RxDoctor Payments Data

Richard Maples, MD

Family Medicine · Redding, CANPI 1174552699

Payments from drug & device makers

$610in general payments, 2019–2025

Across 29 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$89
  • Pfizer$87
  • Medtronic$74
  • Amgen$74
  • AbbVie$69
  • GSK$63
  • plus $154 from 6 others

What the payments were for

  • Food & beverage$610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$610 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,450,644
Medicare patients
3,502
Services billed
14,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$95,918
XareltoRivaroxaban37$39,080
OzempicSemaglutide32$38,627
MounjaroTirzepatide13$24,060
JardianceEmpagliflozin14$22,578
TradjentaLinagliptin14$20,395
TrulicityDulaglutide19$19,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,359
Spiriva RespimatTiotropium Bromide15$14,837
MyrbetriqMirabegron12$14,590
Combivent RespimatIpratropium/Albuterol Sulfate16$14,394
JanuviaSitagliptin Phosphate12$14,114
Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid54$9,145
Breo ElliptaFluticasone/Vilanterol11$8,491
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med105$6,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$95,91875 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat$20$72,20459 claims
Lilly USA, LLCMounjaro, Trulicity$16$43,52932 claims
Novo NordiskOzempic$23$38,62732 claims
GSKTrelegy Ellipta, Breo Ellipta$63$23,85032 claims
AbbVieSynthroid$69$5,43561 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →